Upadacitinib treatment in a real‐world difficult‐to‐treat atopic dermatitis patient cohort

Abstract

AbstractBackgroundUpadacitinib was the first JAK‐1 selective inhibitor registered for the treatment of moderate‐to‐severe atopic dermatitis (AD). Although efficacy and safety have been shown in clinical trials, real‐world data on the use of upadacitinib in patients that have been treated with other immunosuppressants and targeted therapies is limited.ObjectivesTo provide real‐world evidence on the use of upadacitinib treatment in moderate‐to‐severe atopic dermatitis.MethodsIn this prospective observational single‐centre study, all AD patients treated with upadacitinib treatment in the context of standard care were included between August 2021 and September 2022. Clinical outcome measures and adverse events (AEs) were analysed.ResultsForty‐eight patients were included. The majority (n = 39; 81%) had failed (ineffectiveness) on other targeted therapies, including other JAK inhibitors and biologics. Thirty‐four (71%) patients were still using upadacitinib treatment at last follow up (median duration 46.5 weeks). Fourteen (29%) patients discontinued treatment due to ineffectiveness or AE. Upadacitinib treatment led to a significant decrease of disease severity during a median follow up of 37.5 weeks. Median IGA at baseline decreased from 3 (IQR 2–3) to 1.5 (IQR 1–2) at last review (p < 0.001). Median NRS itch decreased from 7 (IQR 5–8) at baseline to 2.25 (IQR 0.25–6.5) at last review (p < 0.001). Three patients discontinued treatment due to AE. Forty‐eight AEs were reported, including acne‐like eruptions (25%), nausea (13%) and respiratory tract infections (10%).ConclusionsIn this real‐world cohort, we confirmed that upadacitinib is an effective treatment in a subset of AD patients that have failed several previous systemic immunosuppressive and biologic treatments. Overall, AE were mostly well tolerated and not a reason to discontinue treatment for most patients.